Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

uniQure (QURE) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may ...

Core Insights - Momentum investors are attracted to fast-growing stocks, particularly in the biopharmaceuticals industry, which presents significant growth potential [2][3] Group 1: uniQure N.V. (NASDAQ: QURE) - uniQure has seen a significant share price increase, with a current price of $59.91 and a 12-month price forecast of $71.75, indicating a 19.76% upside potential [3][5] - The company is known for its adeno-associated viral (AAV) vector platform and has promising drug candidates, including AMT-130 for Huntington's disease and AMT-260 for epilepsy [3][4] - As of Q2, uniQure had $377 million in cash, providing operational runway into 2027 [4] Group 2: Omeros Corp. (NASDAQ: OMER) - Omeros experienced a price spike in mid-October after Novo Nordisk acquired licensing rights to its drug Zaltenibart for $240 million, with a 12-month price forecast of $27.50, representing a 255.30% upside [6][8] - The current price is $7.74, with analysts rating it a Moderate Buy based on 8 ratings [7][9] - Despite a recent price drop, analysts remain optimistic, projecting a potential upside of nearly 244% [9] Group 3: Stardust Power Inc. (NASDAQ: SDST) - Stardust Power, a micro-cap battery tech firm, has a current price of $4.52 and a 12-month price forecast of $51.13, indicating a potential upside of 1,031.08% [10][12] - The company has secured agreements to develop an electric substation and to secure lithium carbonate, which positions it for growth amid rising domestic demand [10][11] - Analysts are bullish, with four out of six rating it a Buy, reflecting confidence in its future prospects [12]

We came across a bullish thesis on uniQure N.V. on Truffle Pigs’s Substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.'s share was trading at $63.65 as of October 9th. QURE’s forward P/E was 27.93 according to Yahoo Finance. Why Core Scientific Inc. (CORZ) Performed Worst On Tuesday? Sergey Nivens/Shutterstock.com uniQure’s AMT-130 represents a groundbreaking advancement in Huntington’s disease, providing the first credible evidence that a gene therapy can meaningfully al ...

​uniQure N.V. (NASDAQ:QURE) is one of the Hot Growth Stocks to Invest in Now. On October 6, Patrick Trucchio from H.C. Wainwright raised the firm’s price target on uniQure N.V. (NASDAQ:QURE) from $70 to $110, while keeping a Buy rating on the stock. The analyst based his bullish sentiment on the promising results from the company’s AMT-130 trials, which were released on September 24. The stock has surged more than 339% since the announcement. The all-important 3-year data from the drug’s phase 1/2 trials ...

uniQure’s (NASDAQ: QURE ) stock skyrocketed in late September after the announcement of stronger-than-expected Huntington’s trial data. Despite a more than 300% increase in the share price, the market still seems to be undervaluing uniQure, which likely stems from uncertainty around the validity of theRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess ...

Company Overview - uniQure N.V. (NASDAQ:QURE) specializes in developing gene therapies for rare and severe diseases, including an approved treatment for hemophilia B called HEMGENIX and clinical candidates for Huntington's disease, epilepsy, ALS, and Fabry disease [2] Clinical Data - On September 24, uniQure announced positive Phase I/II results for its gene therapy candidate AMT-130 targeting Huntington's disease, demonstrating a 75% slowing of disease progression on the composite Unified Huntington's Disease Rating Scale and a 60% improvement on Total Functional Capacity after 36 months compared to a matched control group [2] Market Sentiment - Jim Cramer highlighted the positive clinical data but expressed caution due to an insider selling approximately $9 million worth of stock, indicating potential concerns about the stock's future performance after a significant price increase [1]

Group 1: Ambiq Micro, Albertsons, and uniQure - Ambiq Micro reported quarterly losses of 43 cents per share on sales of $17.90 million on September 4 [1] - RBC Capital analyst maintained Albertsons Companies with an Outperform rating and lowered the price target from $23 to $21 [2] - Wells Fargo analyst maintained uniQure with an Overweight rating and raised the price target from $65 to $80 [2] Group 2: Chevron and LCI Industries - Mizuho analyst maintained Chevron with an Outperform rating and lowered the price target from $192 to $191 [3] - LCI Industries posted better-than-expected earnings for the second quarter on August 5, leading to a buy recommendation from Cramer [3] Group 3: Dillard's - Dillard's reported better-than-expected second-quarter financial results on August 14 [4]

Group 1: Ambiq Micro, Albertsons, and uniQure - Ambiq Micro reported quarterly losses of 43 cents per share on sales of $17.90 million on September 4 [1] - RBC Capital analyst Steven Shemesh maintained an Outperform rating for Albertsons Companies but lowered the price target from $23 to $21 [2] - Wells Fargo analyst Yanan Zhu maintained an Overweight rating for uniQure and raised the price target from $65 to $80 [2] Group 2: Chevron and LCI Industries - Chevron Corporation is viewed positively, with Mizuho analyst Nitin Kumar maintaining an Outperform rating and lowering the price target from $192 to $191 [3] - LCI Industries is recommended as a buy, supported by better-than-expected earnings for the second quarter reported on August 5 [3] Group 3: Dillard's - Dillard's reported better-than-expected second-quarter financial results on August 14, leading to a recommendation to take some profits while allowing the rest to run [4]

uniQure TodayQUREuniQure$54.77 +0.27 (+0.50%) 52-Week Range$4.82▼$60.70Price Target$68.42Add to WatchlistIn one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130. With such a massive spike, uniQure is turning the heads of Wall Street analysts. Most still see upside, implying a high-risk, high-reward opportunity for investors.Get uniQure aler ...